# Pathogenic Mechanisms of Pulmonary Lymphangioleiomyomatosis

> **NIH NIH R01** · CHILDREN'S HOSPITAL OF LOS ANGELES · 2020 · $647,500

## Abstract

Project Summary/Abstract
 Lymphangioleiomyomatosis (LAM), characterized by nodular proliferation of abnormal smooth muscle-
like cells (LAM cells) and pulmonary cysts, is a significant cause of morbidity and mortality in women with
Tuberous Sclerosis Complex (TSC) or with the sporadic form of LAM. LAM is associated with genetic
inactivation of TSC1 or TSC2. Critical knowledge gaps include the heterogeneity of cells within LAM nodules,
the cellular origin of TSC2-deficient LAM cells, and mechanisms underlying the female predominance of LAM.
 Early developmental deletion of Tsc2 (E6.5-E14.5) in lung mesenchyme resulted in nodular pulmonary
lesions in adulthood, predominantly in female mice. These proliferative nodules are composed of cells with loss
of Tsc2 as well as wild-type cells, resembling human LAM nodules. The nodules contain cells expressing
smooth muscle and melanocyte lineage proteins, hallmarks of human LAM. Later developmental deletion of
Tsc2 (E13.5-P1), sparing the pulmonary vasculature, does not result in pulmonary nodular lesions in
adulthood. Metabolic and mitochondrial defects are present in Tsc2-null mesenchymal cells derived from the
pulmonary nodules, compared with wild-type controls. Estrogen stimulates proliferation of these Tsc2-null cells,
but not wild-type cells, and upregulates mitochondrially-derived reactive oxygen species. These and other
preliminary data lead to our central hypothesis: hyperactivation of mTORC1 in subsets of lung mesenchymal
cells leads to estrogen-dependent proliferation of nodular-like lesions, associated with metabolic and
mitochondrial dysfunction, recruitment of extrapulmonary cells and lung destruction.
 Two specific aims are proposed: 1) To dissect the molecular and cellular mechanisms of LAM using a
novel mouse model with spontaneous LAM-like lung lesions. The role of hyperactivated mTORC1 in the
pulmonary LAM-like nodules will be examined using both pharmacologic and genetic approaches. The impact
of Tsc2 deficiency on cellular metabolism and mitochondrial function will be addressed for the first time in lung
mesenchyme-derived cells as a potential mechanism for the abnormal cell growth. The origin of LAM cells and
the mechanisms of recruitment of extrapulmonary mesenchymal cells to LAM-like nodules will be examined
using both parabiosis and allograft models. 2) To determine the specific role of gender in contributing to the
formation and progression of LAM-like nodules in mice with lung mesenchymal Tsc2 deletion. The roles of
estrogen in the pulmonary LAM-like lesions will be investigated in vivo by altering estrogen activity or
simultaneous deletion of ERα/Tsc2 or ERβ/Tsc2 and in vitro by metabolic profiling, RNA-seq, ChIP-seq in
Tsc2-null vs. wild-type cells. This project will have high scientific and clinical impact by filling knowledge
gaps with translational impact for women with LAM and providing a new preclinical therapeutic model.

## Key facts

- **NIH application ID:** 9900580
- **Project number:** 5R01HL146541-02
- **Recipient organization:** CHILDREN'S HOSPITAL OF LOS ANGELES
- **Principal Investigator:** Elizabeth P Henske
- **Activity code:** R01 (R01, R21, SBIR, etc.)
- **Funding institute:** NIH
- **Fiscal year:** 2020
- **Award amount:** $647,500
- **Award type:** 5
- **Project period:** 2019-04-01 → 2023-03-31

## Primary source

NIH RePORTER: https://reporter.nih.gov/project-details/9900580

## Citation

> US National Institutes of Health, RePORTER application 9900580, Pathogenic Mechanisms of Pulmonary Lymphangioleiomyomatosis (5R01HL146541-02). Retrieved via AI Analytics 2026-05-21 from https://api.ai-analytics.org/grant/nih/9900580. Licensed CC0.

---

*[NIH grants dataset](/datasets/nih-grants) · CC0 1.0*